He discusses his session titled “The Microbiome and Fatty Liver Disease,” which he presented at Harvard’s Nonalcoholic Fatty Liver Disease (NAFLD): Mechanisms and Novel Therapeutics symposium.
He talks about the treatment options that are available for treating nonalcoholic fatty liver disease via metabolic pathways. He recently spoke about this topic at the 21st Annual Harvard Nutrition and...
He talks about which metabolic pathways are targeted when treating nonalcoholic fatty liver disease. He recently spoke about this topic at the 21st Annual Harvard Nutrition and Obesity Symposium on NAFLD. ...
Erica Monrose, MD, and Tatyana Kushner, MD, from the Icahn School of Medicine at Mount Sinai, explain the association between nonalcoholic fatty liver disease and intrahepatic cholestasis of pregnancy,...
Manal Abdelmalek, MD, MPH, from Duke University, answers our questions about the challenges in the diagnosis and staging of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Dr Harrison discusses key takeaways for gastroenterologists and hepatologists about the management of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Dr Harrison highlights the importance of new treatment options for patients with nonalcoholic steatohepatitis, discusses findings from the REGENERATE clinical trial presented at the ACG 2019 Annual Meeting,...
He gives an overview of his session at our upcoming Cardiometabolic Risk Summit, which includes a discussion about non-alcoholic fatty liver disease, how fat affects the liver, and why patients (and...
Dr Loo and Dr Chen highlight the current management of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, obesity as a risk factor for the diseases, and more.
Now that hepatitis C is highly curable in the DAA era, a greater focus is shifting towards non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. We discussed this further with Jagpreet...
